Publications

NASH-TAG 2024

• Hepatic Functional Improvement Detected by Hepquant Duo Within 120 Days of Treatment With Rencofilstat (Rcf) in Mash Subjects with ≥ F3 Fibrosis

7th Obesity & NASH Drug Development Summit

• Using AI/ML and Multi-Omics to Determine Efficacy for Clinical NASH Study Enrichment: Highlights from Recently Completed Phase 2 Trials with Rencofilstat

AASLD 2023

• Use of Agile 3+ as a Screening Tool Successfully Targets F3 MASH Subjects with Impaired Hepatic Function and Portal-Systemic Shunting Evaluated by HepQuant SHUNT Test: Lessons Learned From the Hepion Altitude-NASH Trial
• Hepatic Functional Improvement Detected by HepQuant DuO Within 120 Days of Treatment with Rencofilstat (Rcf) in MASH Subjects with ≥ F3 Fibrosis

EASL 2023

• Cyclophilin inhibition exhibits preventive and curative antifibrotic effects via extracellular matrix remodelling
• Cyclophilin inhibition with rencofilstat shifts the liver transcriptome and lipidome in preclinical models toward resolution of nonalcoholic steatohepatitis
• Mice lacking Cyclophilin B, but not Cyclophilin A, are significantly protected from the development of major features of NAFLD/NASH in a diet and chemical-induced model

AACR 2023

• Rencofilstat Exerts a Dominant Role in Synergistic Anti-PD1-Combination Effects in a Fatty Liver Model of Hepatocellular Carcinoma

Global NASH Congress 2023

• Rencofilstat (CRV431): Update on NASH Clinical Program

NASH-TAG 2023

• Rencofilstat Multiomics Data Indicate Clinically Important Mechanisms in NAFLD-NASH

AFDD 2022

• Multi-Organ Antifibrotic Activity by Rencofilstat Through Inhibition of the Collagen-Regulating Enzyme, Cyclophilin B

AASLD The Liver Meeting® 2022

• The Effect of Rencofilstat on the Multi-Omics of Biomarker Assessed F2/F3 NASH Subjects
• Cyclophilin B Knockout Significantly Limits the Development of Liver Fibrosis in a diet-and Chemical-Induced Mouse Model of NAFLD/NASH

ISBRA & ESBRA 2022

• Cyclophilin inhibitor Rencofilstat as a potential therapy for Alcohol related Liver Disease

Global Nash Congress 2022

• Rencofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC

NASH-TAG 2022

• Rencofilstat (CRV431) in NASH Patients: The Phase 2a AMBITION Study

EASL 2022

• Cyclophilin D knockout promotes cell death pathways in preventing HCC development in a streptozotocin induced mouse model of diabetes-linked NASH
• Synergistic anti-tumor activity with a combination of anti-PD1 antibody and the cyclophilin inhibitor, rencofilstat, in the Hep53.4 fatty liver model of hepatocellular carcinoma
• Rencofilstat, a pan-cyclophilin inhibitor, exerts diverse metabolic and transcriptional anti-tumor activities in a murine NASH-HCC model
• Cyclophilin inhibitor CRV431 (Rencofilstat) as a potential therapy for ALD
• Integrated transcriptomics of Rencofilstat treatment in a Phase 2a NASH trial confirms anti-fibrotic effect of pan-cyclophilin inhibition and identifies Rencofilstat-specific biomarkers

AASLD The Liver Meeting® 2021

• Investigating CRV431 in NASH Patients: Data From the Phase 2a AMBITION Study

Global NASH Congress 2021

• CRV431: From Benchtop to Bedside Clinical Development

NASH-TAG 2021

• Overview of Rencofilstat

NASH Summit 2020

• Pleiotropic Actions of the Cyclophilin Inhibitor, CRV431, in Preclinical Models

EASL 2020

• CRV431 decreases diet- and chemical-driven fibrosis in livers of mice

AASLD The Liver Meeting® 2020

• Superior Antifibrotic Efficacy of CRV431 in Human Precision Cut Liver Slices

NASH-TAG 2020

• CRV431 Directly Targets Liver Fibrosis in Murine NASH Models and Human Liver Slices

EASL 2019

• A Phase 1 Single Ascending Dose Study of CRV431

AASLD The Liver Meeting® 2019

• CRV431 Targets the Liver and Decreases Liver Fibrosis in the Carbon Tetrachloride Mouse Model

Hep Dart 2019

• Population Pharmacokinetic (PopPK) Analysis of CRV431 in a Phase I Clinical Trial

The International Liver Congress 2018

• HBV Peptide Array Demonstrates Candidates Mechanisms of CRV431 Anti-HBV Activity

EASL 2018

• Assessing the in vitro anti-HBV activity of combinations including CRV431, TXL and prototype core protein assembly modulators

AASLD The Liver Meeting® 2018

• CRV431, a Cyclophilin Inhibitor, Reduces Fibrosis and Tumor Burden in Mice with Hepatocellular Carcinoma

Hep Dart 2017

• CRV431: Multiple Therapeutic Actions In Vitro and In Vivo

AASLD The Liver Meeting® 2017

• CRV431 Blocks NTCP-Mediated Uptake of HBV and HDV Independently of Effects on Bile Acid Transport
• Independent and Combinational Anti-HBV Effects of CRV431 and TXL in the HBV Transgenic Mouse Model

EASL 2017

• The cyclophilin inhibitor CRV431 prevents both HBx-cyclophilin complex formation and HBV replication
• CRV431 and CMX157 (TXL; tenofovir exalidex) – Anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug

APASL 2017

• In Vitro Metabolism of CRV431, a Novel Cyclophilin Inhibitor for the Treatment of HBV

AASLD The Liver Meeting® 2016

• CRV431: An Optimized Cyclophilin Inhibitor with Multiple Anti-HBV Activities, High Selectivity Index, and Synergy with CMX157

• The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
• Effect of a High‐Fat Meal on Single‐Dose Rencofilstat (CRV431) Oral Bioavailability in Healthy Human Subjects
• Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH
• Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice 2020
• A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
• Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis NASH
• The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
• Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System
• In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B
• The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action

• Non-Immunosuppressive Cyclophilin Inhibitors
• Structural and Functional Insights into Human Nuclear Cyclophilins
• Molecular insights into prolyl and lysyl hydroxylation of fibrillar collagens in health and disease
• Cyclophilin inhibition as potential therapy for liver diseases
• Functional aspects of extracellular cyclophilins
• Cyclophilin A: a key player for human disease
• Structural and Biochemical Characterization of the Human Cyclophilin Family of Peptidyl-Prolyl Isomerases
• Prolyl cis-trans isomerization as a molecular timer